ENTRY       D09920                      Drug
NAME        Lenvatinib mesylate (USAN);
            Lenvatinib mesilate (JAN);
            Lenvima (TN)
PRODUCT     LENVIMA (Eisai)
FORMULA     C21H19ClN4O4. CH4SO3
EXACT_MASS  522.0976
MOL_WEIGHT  522.9586
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG01917  Receptor tyrosine kinase inhibitor
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
            Transporter substrate
             DG01665  ABCB1 substrate
REMARK      Therapeutic category: 4291
            ATC code: L01EX08
            Chemical structure group: DG01362
            Product (DG01362): D09920<JP/US>
EFFICACY    Antineoplastic, Receptor tyrosine kinase inhibitor
  DISEASE   Thyroid cancer [DS:H00032]
            Renal cell carcinoma [DS:H00021]
            Hepatocellular carcinoma [DS:H00048]
            Endometrial cancer [DS:H00026]
TARGET      VEGFR1 (FLT1) [HSA:2321] [KO:K05096]
            VEGFR2 (KDR) [HSA:3791] [KO:K05098]
            VEGFR3 (FLT4) [HSA:2324] [KO:K05097]
            FGFR [HSA:2260 2263 2261 2264] [KO:K04362 K05093 K05094 K05095]
            RET [HSA:5979] [KO:K05126]
  PATHWAY   hsa04010(2260+2261+2263+2264+2321+2324+3791)  MAPK signaling pathway
            hsa04370(3791)  VEGF signaling pathway
            hsa05200(2260+2261+2263+2264+2324+5979)  Pathways in cancer
            hsa05216(5979)  Thyroid cancer
METABOLISM  Enzyme: CYP3A [HSA:1576 1577 1551]
            Transporter: ABCB1 [HSA:5243]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01E PROTEIN KINASE INHIBITORS
                L01EX Other protein kinase inhibitors
                 L01EX08 Lenvatinib
                  D09920  Lenvatinib mesylate (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Molecular Target Inhibitors
               Lenvatinib
                D09920  Lenvatinib mesylate (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D09920  Lenvatinib mesylate (USAN); Lenvatinib mesilate (JAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                DG01362  Lenvatinib
                 D09920  Lenvatinib mesylate
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG01362  Lenvatinib
                D09920  Lenvatinib mesylate
             Transporter substrate
              DG01665  ABCB1 substrate
               DG01362  Lenvatinib
                D09920  Lenvatinib mesylate
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               FGFR family
                FGFR
                 D09920  Lenvatinib mesylate (USAN) &lt;JP/US&gt;
               VEGFR family
                VEGFR1 (FLT1)
                 D09920  Lenvatinib mesylate (USAN) &lt;JP/US&gt;
                VEGFR2 (KDR)
                 D09920  Lenvatinib mesylate (USAN) &lt;JP/US&gt;
                VEGFR3 (FLT4)
                 D09920  Lenvatinib mesylate (USAN) &lt;JP/US&gt;
               RET family
                RET
                 D09920  Lenvatinib mesylate (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09920
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09920
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09920
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09920
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D09920
             Drug transporters
              D09920
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                DG01362  Lenvatinib
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG01362  Lenvatinib
             Transporter substrate
              DG01665  ABCB1 substrate
               DG01362  Lenvatinib
DBLINKS     CAS: 857890-39-2
            PubChem: 135626657
            ChEBI: 85995
            LigandBox: D09920
ATOM        35
            1   C8y C    12.8800  -22.4700
            2   C8y C    12.8800  -23.8700
            3   C8x C    14.1400  -24.5700
            4   C8y C    15.3300  -23.8700
            5   C8y C    15.3300  -22.4700
            6   C8x C    14.1400  -21.7700
            7   C8y C    16.5200  -24.5700
            8   C8x C    17.7800  -23.8700
            9   C8x C    17.7800  -22.4700
            10  N5x N    16.5200  -21.7700
            11  O2a O    16.5200  -25.9700
            12  C8y C    17.7800  -26.6700
            13  C8x C    17.7800  -28.0700
            14  C8y C    18.9700  -28.7700
            15  C8y C    20.1600  -28.0700
            16  C8x C    20.1600  -26.6700
            17  C8x C    18.9700  -25.9700
            18  O2a O    11.6900  -21.7700
            19  C5a C    11.6900  -24.5700
            20  N1a N    10.5000  -23.8700
            21  O5a O    11.6900  -25.9700
            22  X   Cl   18.9700  -30.1700
            23  N1b N    21.4200  -28.7700
            24  C5a C    22.6100  -28.0700
            25  N1b N    23.8000  -28.7700
            26  O5a O    22.6100  -26.6700
            27  C1a C    10.5000  -22.4000
            28  C1y C    24.9900  -28.0700
            29  C1x C    26.3900  -28.0700
            30  C1x C    25.6900  -26.8100
            31  C1a C    21.2100  -23.1700
            32  S4a S    22.6100  -23.1700
            33  O1d O    24.0100  -23.1700
            34  O1d O    22.6100  -21.7700
            35  O1d O    22.6100  -24.5700
BOND        37
            1     1   2 1
            2     2   3 2
            3     3   4 1
            4     4   5 2
            5     5   6 1
            6     1   6 2
            7     4   7 1
            8     7   8 2
            9     8   9 1
            10    9  10 2
            11    5  10 1
            12    7  11 1
            13   11  12 1
            14   12  13 2
            15   13  14 1
            16   14  15 2
            17   15  16 1
            18   16  17 2
            19   12  17 1
            20    1  18 1
            21    2  19 1
            22   19  20 1
            23   19  21 2
            24   14  22 1
            25   15  23 1
            26   23  24 1
            27   24  25 1
            28   24  26 2
            29   18  27 1
            30   25  28 1
            31   28  29 1
            32   28  30 1
            33   30  29 1
            34   31  32 1
            35   32  33 1
            36   32  34 2
            37   32  35 2
///
